Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Cardinal Capital Management

Cardinal Capital Management lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,774 shares of the biopharmaceutical company’s stock after buying an additional 284 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.2% of Cardinal Capital Management’s holdings, making the stock its 27th largest holding. Cardinal Capital Management’s holdings in Regeneron Pharmaceuticals were worth $7,482,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Norges Bank purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $932,571,000. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares in the last quarter. Global Assets Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $339,594,000. First Trust Advisors LP grew its position in shares of Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares in the last quarter. Finally, abrdn plc increased its stake in shares of Regeneron Pharmaceuticals by 552.8% in the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after buying an additional 186,215 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. JPMorgan Chase & Co. increased their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Argus lifted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.91.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,397,202. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,397,202. The disclosure for this sale can be found here. In the last three months, insiders sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $18.30 during trading on Thursday, reaching $1,050.86. 502,643 shares of the company’s stock were exchanged, compared to its average volume of 477,991. The firm has a market cap of $115.79 billion, a PE ratio of 31.17, a P/E/G ratio of 2.21 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,081.17. The company’s fifty day moving average price is $978.05 and its 200-day moving average price is $948.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.